The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial
Open accessThe DOI matches its Crossref record.
Abstract
Studies in the 1970s and 1980s reported that bacterial lysates (BL) had a prophylactic effect on recurrent respiratory tract infections (RRTI). However, controlled clinical study procedures have evolved substantially since then. We performed a trial using updated methods to evaluate the efficacy of Lantigen B®, a chemical BL. This double blind, placebo controlled, multi-center clinical trial had the primary objective of assessing the capacity of Lantigen B to significantly reduce the total number of infectious episodes in patients with RRTI. Secondary aims were the RRTI duration, the frequency and the severity of the acute episodes, the use of drugs and the number of missed workdays. In the subgroup of allergic patients with RRTI, the number of allergic episodes (AE) and the use of anti-allergic drugs were also evaluated. One hundred and sixty patients, 79 allocated to the treated group (TG) and 81 to the placebo group (PG), were enrolled; 30 were lost during the study and 120 (79 females and 38 males) were evaluated. The PG had 1.43 episodes in the 8-months of follow-up while the TG had 0.86 episodes (p=0.036). A similar result was observed in the allergic patients (1.80 and 0.86 episodes for the PG and the TG, respectively, p=0.047). The use of antibiotics was reduced (mean 1.24 and 2.83 days of treatment for the TG and the PG). Logistic regression analysis indicated that the estimated risk of needing antibiotics and NSAIDs was reduced by 52.1 and 30.6%, respectively. With regard to the number of AE, no significant difference was observed between the two groups, but bronchodilators, antihistamines and local corticosteroids were reduced by 25.7%, 56.2% and 41.6%, respectively, in the TG. Lantigen B significantly reduced the number of infectious episodes in patients with RRTI. This finding suggests a first line use of this drug for the prophylaxis of infectious episodes in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Salminen, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., Sanders, M. E., Shamir, R., Swann, J. R., Szajewska, H., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00440-6 · Cited by 2,488
Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0344-2 · Cited by 2,196
Vinderola, G., Druart, C., Gosálbez, L., Salminen, S., Vinot, N., & Lebeer, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1239745 · Cited by 52
Postbiotics as potential new therapeutic agents for sepsis
Lou, X., Xue, J., Shao, R., Mo, C., Wang, F., & Chen, G. (2023) · Burns & Trauma · doi:10.1093/burnst/tkad022 · Cited by 38
Metadata
- Authors
- Braido, F., Melioli, G., Candoli, P., Cavalot, A., Di Gioacchino, M., Ferrero, V., Incorvaia, C., Mereu, C., Ridolo, E., Rolla, G., Rossi, O., Savi, E., Tubino, L., Reggiardo, G., Baiardini, I., di Marco, E., Rinaldi, G., Canonica, G. W., Accorsi, C., Bossilino, C., Bonzano, L., DiLizia, M., Fedrighini, B., Garelli, V., Gerace, V., Maniscalco, S., Massaro, I., Messi, A., Milanese, M., Peveri, S., Penno, A., Pizzimenti, S., Pozzo, T., Raie, A., Regina, S., & Sclifò, F.
- Venue
- Immunology Letters
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 162
- Issue
- 2
- Pages
- 185-193
- ISSN
- 0165-2478 (ISSN-L)
- OpenAlex
- W2083886115
- Cited by
- 25
- References
- 0
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial. https://app.cochat.ai/papers/10.1016/j.imlet.2014.10.026
- The paper
- Braido, F., Melioli, G., Candoli, P., Cavalot, A., Di Gioacchino, M., Ferrero, V., Incorvaia, C., Mereu, C., Ridolo, E., Rolla, G., Rossi, O., Savi, E., Tubino, L., Reggiardo, G., Baiardini, I., di Marco, E., Rinaldi, G., Canonica, G. W., Accorsi, C., . . . Sclifò, F. (2014). The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial. Immunology Letters. https://doi.org/10.1016/j.imlet.2014.10.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.